ARTICLE | Finance
Buying American
Why OrbiMed is backing away from Europe with newest venture fund
January 4, 2016 8:00 AM UTC
Even though OrbiMed Advisors just scored a massive win with Dutch cancer company Acerta Pharma B.V., the firm's new $950 million venture fund is unlikely to be active in Europe.
"We've essentially stopped raising capital from Europe because it's so unfriendly," said OrbiMed's Carter Neild. ...